On June 10, 2026, Fennec Pharmaceuticals Inc. (the "Company") held an annual meeting of shareholders (the "Meeting"). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:

1. The following five (5) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:

2. The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:

3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:

4. The resolution to vote on the advisory vote on the frequency of advisory votes on compensation of Corporations named executive officers was approved based on the following vote:

5. The resolution to approve certain amendments to Corporation's 2020 Equity Incentive Plan was approved based on the following vote:

(1) An aggregate of 766,153 common shares, representing the aggregate number of shares held by officers and directors of the Corporation, has been deducted from the FOR vote in respect of this resolution.

6. The resolution to ratify and approve the adoption of Fennec's 2026 Equity Inducement Plan was approved based on the following vote:.